A mere few days following the FDA’s approval of Trikafta, cystic fibrosis patients across the United States began dosing. This week’s podcast looks back at Gunnar’s time in the triple combo study. Think of this podcast as a follow to Gunnar’s blog. Gunnar talks about both the immediate and long term affects of having been on the medication and what his hopes are for the CF community. Gunnar and Tiffany reaffirm the scientific community’s commitment to a treatment for the final 10% of CF patients and a cure for all CF patients.